Cytoprotective effect of novel histone deacetylase inhibitors against polyglutamine toxicity

Neuroscience Letters

Volumn 392, Issue 3, 2006, Pages 213-215

  Kariya, Shingo ^a   Hirano, Makito ^a   Uesato, Shinichi ^b,c   Nagai, Yoshitaka ^d   Nagaoka, Yasuo ^b,c   Furiya, Yoshiko ^a   Asai, Hirohide ^a   Fujikake, Nobuhiro ^d   Toda, Tatsushi ^d   Ueno, Satoshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c KANSAI UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Ataxia; Dentatorubral pallidoluysian atrophy; Epilepsy; Histone deacetylase inhibitor; Hydroxamic acid residue; N Hydroxycarboxamide

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; K 110; K 120; K 140; K 32; POLYGLUTAMINE; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DRUG EFFECT; DRUG SCREENING; DRUG STRUCTURE; GENETIC TRANSFECTION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURAL HOMOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; CANTHARIDIN; CELL COUNT; CELL DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HISTONE DEACETYLASES; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; PC12 CELLS; PEPTIDES; RATS; TRANSFECTION;

EID: 28444453738     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2005.09.019     Document Type: Article

References (10)

1. M.A. Carducci, J. Gilbert, M.K. Bowling, D. Noe, M.A. Eisenberger, V. Sinibaldi, Y. Zabelina, T.L. Chen, L.B. Grochow, and R.C. Donehower A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule Clin. Cancer Res. 7 2001 3047 3055
2. E. Hockly, V.M. Richon, B. Woodman, D.L. Smith, X. Zhou, E. Rosa, K. Sathasivam, S. Ghazi-Noori, A. Mahal, P.A. Lowden, J.S. Steffan, J.L. Marsh, L.M. Thompson, C.M. Lewis, P.A. Marks, and G.P. Bates Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease Proc. Natl. Acad. Sci. U.S.A. 100 2003 2041 2046
3. I. Kanazawa Dentatorubral-pallidoluysian atrophy or Naito-Oyanagi disease Neurogenetics 2 1998 1 17
4. S. Kariya, M. Hirano, Y. Nagai, Y. Furiya, N. Fujikake, T. Toda, and S. Ueno Humanin attenuates apoptosisi nduced by DRPLA proteins with expanded polyglutamine stretches J. Mol. Neurosci. 25 2005 165 170
5. A. McCampbell, A.A. Taye, L. Whitty, E. Penney, J.S. Steffan, and K.H. Fischbeck Histone deacetylase inhibitors reduce polyglutamine toxicity Proc. Natl. Acad. Sci. U.S.A. 98 2001 15179 15184
6. M. Minamiyama, M. Katsuno, H. Adachi, M. Waza, C. Sang, Y. Kobayashi, F. Tanaka, M. Doyu, A. Inukai, and G. Sobue Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy Hum. Mol. Genet. 13 2004 1183 1192
7. Y. Nagai, T. Tucker, H. Ren, D.J. Kenan, B.S. Henderson, J.D. Keene, W.J. Strittmatter, and J.R. Burke Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening J. Biol. Chem. 275 2000 10437 10442
8. J.S. Steffan, L. Bodai, J. Pallos, M. Poelman, A. McCampbell, B.L. Apostol, A. Kazantsev, E. Schmidt, Y.Z. Zhu, M. Greenwald, R. Kurokawa, D.E. Housman, G.R. Jackson, J.L. Marsh, and L.M. Thompson Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila Nature 413 2001 739 743
9. S. Uesato, M. Kitagawa, Y. Nagaoka, T. Maeda, H. Kuwajima, and T. Yamori Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group Bioorg. Med. Chem. Lett. 12 2002 1347 1349
10. M. Yoshida, M. Kijima, M. Akita, and T. Beppu Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A J. Biol. Chem. 265 1990 17174 17179